{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=docetaxel&page=3", "query": { "intervention": "docetaxel", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 1320, "total_pages": 132, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=docetaxel&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=docetaxel&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-23T12:33:48.876Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00273546", "title": "Induction Chemotherapy Comparing Taxotere® Cisplatin and 5-Fluorouracil (TPF) With Standard Cisplatin and 5-Fluorouracil (PF) Followed by Chemoradiation in Locally Advanced Head and Neck Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "XRP6976 (Docetaxel/Taxotere)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 500, "start_date": "1999-05", "completion_date": "2006-02", "has_results": false, "last_update_posted_date": "2009-04-29", "last_synced_at": "2026-10-23T12:33:48.876Z", "location_count": 1, "location_summary": "Bridgewater, New Jersey", "locations": [ { "city": "Bridgewater", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00273546" }, { "nct_id": "NCT00030420", "title": "Celecoxib and Docetaxel in Treating Patients With Advanced Non-Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lung Cancer" ], "interventions": [ { "name": "Celecoxib", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Barbara Ann Karmanos Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2001-10", "completion_date": "2008-02", "has_results": false, "last_update_posted_date": "2013-04-29", "last_synced_at": "2026-10-23T12:33:48.876Z", "location_count": 1, "location_summary": "Detroit, Michigan", "locations": [ { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT00030420" }, { "nct_id": "NCT02607423", "title": "Fludeoxyglucose F-18 PET/CT in Predicting Response to Chemotherapy in Patients With Stage IIIA Non-small Cell Lung Cancer That Can Be Removed by Surgery", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Stage IIIA Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "Cisplatin", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Fludeoxyglucose F-18", "type": "RADIATION" }, { "name": "Gemcitabine Hydrochloride", "type": "DRUG" }, { "name": "Pemetrexed Disodium", "type": "DRUG" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "ECOG-ACRIN Cancer Research Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2015-11-19", "completion_date": "2017-01-31", "has_results": false, "last_update_posted_date": "2023-05-25", "last_synced_at": "2026-10-23T12:33:48.876Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02607423" }, { "nct_id": "NCT06046482", "title": "Phase II Trial of Magrolimab and Cetuximab With Pembrolizumab or Docetaxel for Recurrent/Metastatic Head Neck Squamous Cell Carcinoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Head Neck", "Squamous Cell Carcinoma of Head and Neck" ], "interventions": [ { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Magrolimab", "type": "DRUG" }, { "name": "cetuximab", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4, "start_date": "2023-11-28", "completion_date": "2024-08-26", "has_results": true, "last_update_posted_date": "2025-10-22", "last_synced_at": "2026-10-23T12:33:48.876Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06046482" }, { "nct_id": "NCT02379585", "title": "Fasting on Newly Diagnosed Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "HER2-positive Breast Cancer" ], "interventions": [ { "name": "Doxorubicin", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "docetaxel", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" }, { "name": "Pertuzumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Western Regional Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 8, "start_date": "2013-01", "completion_date": "2015-08", "has_results": true, "last_update_posted_date": "2018-04-24", "last_synced_at": "2026-10-23T12:33:48.876Z", "location_count": 1, "location_summary": "Goodyear, Arizona", "locations": [ { "city": "Goodyear", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT02379585" }, { "nct_id": "NCT06545955", "title": "A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non-muscle Invasive Bladder Cancer With Carcinoma in Situ" ], "interventions": [ { "name": "Nadofaragene Firadenovec", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ferring Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 250, "start_date": "2024-10-01", "completion_date": "2030-12-31", "has_results": false, "last_update_posted_date": "2026-09-25", "last_synced_at": "2026-10-23T12:33:48.876Z", "location_count": 40, "location_summary": "Tucson, Arizona • Little Rock, Arkansas • Los Angeles, California + 34 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06545955" }, { "nct_id": "NCT01083615", "title": "A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Castrate-Resistant Prostate Cancer", "Hormone Refractory Prostate Cancer" ], "interventions": [ { "name": "custirsen sodium", "type": "DRUG" }, { "name": "isotonic, 0.9% sodium chloride", "type": "DRUG" }, { "name": "docetaxel", "type": "DRUG" }, { "name": "cabazitaxel", "type": "DRUG" }, { "name": "prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Achieve Life Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "MALE", "summary": "18 Years to 99 Years · Male only" }, "enrollment_count": 14, "start_date": "2010-03", "completion_date": "2013-03", "has_results": false, "last_update_posted_date": "2016-10-12", "last_synced_at": "2026-10-23T12:33:48.876Z", "location_count": 20, "location_summary": "La Verne, California • Fort Lauderdale, Florida • Tampa, Florida + 17 more", "locations": [ { "city": "La Verne", "state": "California" }, { "city": "Fort Lauderdale", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Honolulu", "state": "Hawaii" }, { "city": "Urbana", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01083615" }, { "nct_id": "NCT02605915", "title": "Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HER2-Positive Metastatic Breast Cancer", "HER2-Negative Metastatic Breast Cancer", "Locally Advanced or Early Breast Cancer" ], "interventions": [ { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Pertuzumab", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" }, { "name": "Trastuzumab emtansine", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 98, "start_date": "2015-12-31", "completion_date": "2019-11-13", "has_results": false, "last_update_posted_date": "2020-02-05", "last_synced_at": "2026-10-23T12:33:48.876Z", "location_count": 20, "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • Joliet, Illinois + 17 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Joliet", "state": "Illinois" }, { "city": "Lafayette", "state": "Indiana" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02605915" }, { "nct_id": "NCT05671510", "title": "ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non Small Cell Lung Cancer" ], "interventions": [ { "name": "Gotistobart", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "OncoC4, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 630, "start_date": "2023-06-28", "completion_date": "2028-08-31", "has_results": false, "last_update_posted_date": "2026-08-13", "last_synced_at": "2026-10-23T12:33:48.876Z", "location_count": 46, "location_summary": "Dothan, Alabama • Russellville, Arkansas • Cerritos, California + 42 more", "locations": [ { "city": "Dothan", "state": "Alabama" }, { "city": "Russellville", "state": "Arkansas" }, { "city": "Cerritos", "state": "California" }, { "city": "Redlands", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05671510" }, { "nct_id": "NCT00012311", "title": "Chemotherapy Plus Peripheral Stem Cell Transplantation Compared With Chemotherapy Alone in Treating Women With Stage IV Breast Cancer", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "CMF regimen", "type": "DRUG" }, { "name": "carboplatin", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "docetaxel", "type": "DRUG" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "fluorouracil", "type": "DRUG" }, { "name": "ifosfamide", "type": "DRUG" }, { "name": "methotrexate", "type": "DRUG" }, { "name": "thiotepa", "type": "DRUG" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "Herbert Irving Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "59 Years", "sex": "FEMALE", "summary": "18 Years to 59 Years · Female only" }, "enrollment_count": null, "start_date": "2000-01", "completion_date": null, "has_results": false, "last_update_posted_date": "2014-01-06", "last_synced_at": "2026-10-23T12:33:48.876Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00012311" } ] }